Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa trial of HBM4003 in combination therapy with toripalimab (anti-PD-1 antibody) for patients suffering from advanced melanoma and other solid tumors

Next Previous
Trial Profile

A Phase Ib/IIa trial of HBM4003 in combination therapy with toripalimab (anti-PD-1 antibody) for patients suffering from advanced melanoma and other solid tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Porustobart (Primary) ; Toripalimab (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Harbour BioMed

Most Recent Events

  • 25 Nov 2022 According to a Harbour BioMed media release, data from the trial will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress.
  • 01 Jun 2022 According to a Harbour BioMed media release, phase 1a clinical data for the trial was presented at the ASCO annual meeting 2022.
  • 01 Mar 2022 According to a Harbour BioMed media release, the company has completed patient enrollment in the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top